Speaker- Dr. Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations, LLCAnnouncements-
The money we had raised last year was finally donated. The school we donated the money to had 3 microscopes, only one of them actually usable though. They bought a digital microscope camera with the money so all of the students could see the images.
Bake Sale will be on November 28 in the Biochemistry Building. If you signed up for a time to work please be in the Biochemistry Building on time. If you signed up to bring an item, please drop it off as soon as possible. You need to label those baked goods that contain peanuts, peanut butter, and other common allergies, and please wrap the baked goods
Faculty Dinner will be on November 29, Thursday at 6pm. If you RSPV to Sherry please do come. It is going to be a great fiesta!
Below is the schedule of meetings for next semester. We need ideas for speakers. If you have an idea or particular interest email Kayleigh (email@example.com) or Lotti (firstname.lastname@example.org) before dead week.
January 10- Social
April 18- Spring Faculty Dinner
Speaker- Dr. Anton Iliuk, President and Chief Technology Officer, Tymora Analytical Operations, LLCDevelopment of Commercialized Products
There are different levels of control in gene expression. PTMs provide huge variability and are the ultimate proteome diversification. Phosphorylation is in all aspects of cell life. At all time, one third of the proteins within an organism are phosphorylated. A kinase takes the phosphate from ADP and puts it onto an enzyme. Gleevec was the first FDA approved kinase inhibitor. It was said to be the “wonder drug” for cancer treatment. Cancer causes mis-regulation in phosphorylation. Phosphorylation is hard to study because it is so diverse. This causes little drug approval when dealing with phosphorylation. Drug companies try to reduce costs in drug discovery and preclinical steps. Usually the drugs designed to affect phosphorylation have high effectiveness, but the scope of its use decreases. pIMAGO is the molecule that Dr. Iliuk developed. It binds only to phospho-proteins. It is used mainly for kinase inhibitor screening.
When forming a company,
you need to ask yourself three questions.
- So what? - does it provide an improvement on
- Who cares? - academic labs, research
- Why you? - Inventors on board, ability of others
to make product(s) as well?